SPRY Stock Forecast & Price Target

ARS Pharmaceuticals is supported by neffy’s differentiated, needle-free profile, which addresses a large and growing epinephrine market hindered by painful, inconvenient autoinjectors, while its rapid PK/PD performance has been shown to be comparable to intramuscular epinephrine and EpiPen in clinical trials. Although the July 1, 2026 formulary cycle did not deliver a major commercial catalyst, management said access remains broad through existing coverage and the $199 retail cash-pay option, Florida Medicaid added neffy effective July 1, 2026, 2026 OpEx was lowered to about $248M, and the 2027 cash-flow breakeven goal was reaffirmed. Beyond the core launch, the company has meaningful upside from ALK’s $145M upfront payment, expected long-term royalties and milestones, and the underappreciated CSU opportunity, where Phase 2b interim data are expected in 4Q26 and the asset could support premium pricing and substantial future sales.

ARS Pharmaceuticals is exposed to a fragile launch thesis because the commercial outlook for neffy depends heavily on physician confidence that intranasal delivery is as reliable as injectable epinephrine, while adoption may be slow outside allergists and could face competing delivery approaches. The company also appears vulnerable to payer friction, as patient cost-sharing, possible prior authorization, and plans questioning a higher price for a lower-dose product could suppress uptake and limit breadth of access. The lack of new July 1 formulary additions or coverage decisions removed a near-term catalyst, leaving shares more dependent on execution than on visible demand traction.